Associations of proinflammatory cytokines with the risk of recurrent stroke

Stroke

Volumn 39, Issue 8, 2008, Pages 2226-2230

  Welsh, Paul ^a   Lowe, Gordon D O ^a   Chalmers, John ^b   Campbell, Duncan J ^c   Rumley, Ann ^a   Neal, Bruce C ^b   MacMahon, Stephen W ^b   Woodward, Mark ^a,b,d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute phase response; Epidemiology; Inflammation; Stroke

Indexed keywords

ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INTERLEUKIN 18; INTERLEUKIN 6; PERINDOPRIL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; ACUTE PHASE RESPONSE; BLOOD; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ACUTE-PHASE REACTION; AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; CYTOKINES; FEMALE; FIBRINOGEN; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RISK FACTORS; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49849103941     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.504498     Document Type: Article

References (39)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost. 2005;3:1618-1627.
3. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36: 1316-1329.
4. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799-1809.
5. Everett BM, Kurth T, Buring JE, Ridker PM. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol. 2006;48:2235-2242.
6. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. 2007;115:2119-2127.
7. Bos MJ, Schipper CM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation. 2006;114:1591-1598.
8. Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, Neal BC, Patel A, Jenkins AJ, Kemp BE, MacMahon SW. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005;36:2143-2147.
9. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MFG, Warlow CP, Cerebrovascular Cohort Studies Collaboration. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35:2300-2305.
10. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
11. Pradhan AD, Manson JE, Rossow JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288:980-987.
12. Lowe GD, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol. 2004;24:1529-1534.
13. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rup-prechtHJ, AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002; 106:24-30.
14. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453-2459.
15. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101: 2149-2153.
16. Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, Pyorala K. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-α in the prognostic classification of unstable angina pectoris. Ann Med. 2001;33:37-47.
17. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108:2317-2322.
18. Kip KE, Marroquin OC, Shaw LJ, Arant CB, Wessel TR, Olson MB, Johnson BD, Mulukutla S, Sopko G, Merz CN, Reis SE. Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J. 2005;150: 900-906.
19. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Munzel T, Yusuf S, HOPE Study Investigators. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114:201-208.
20. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598-1603.
21. Barath P, Fishbein M, Cao J, Berenson J, Helfant R, Forrester J. Detection and localization of tumor necrosis factor in human atheroma. Am J Pathol. 1990;65:297-302.
22. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002;195:245-257.
23. Canault M, Peiretti F, Mueller C, Kopp F, Morange P, Rihs S, Portugal H, Juhan-Vague I, Nalbone G. Exclusive expression of transmembrane TNF-α in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis. 2004;172:211-218.
24. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsspn J, Jovinge S. Inhibition of tumour necrosis factor-α reduces atherosclerosis in apoli-poprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004;24: 2137-2142.
25. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ, Trautwein C, Luchtefeld M, Schmittkamp C, Heeneman S, Daemen MJ, Drexler H. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004;110: 3493-3500.
26. Yamada Y, Metoki N, Yoshida H, Satoh K, Ichihara S, Kato K, Kameyama T, Yokoi K, Matsuo H, Segawa T, Watanabe S, Nozawa Y. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vasc Biol. 2006;26:1920-1925.
27. Lalouschek W, Schillinger M, Hsieh K, Endler G, Greisenegger S, Marculescu R, Lang W, Wagner O, Cheng S, Mannhalter C. Polymorphisms of the inflammatory system and risk of ischemic cerebrovascular events. Clin Chem Lab Med. 2006;44:918-923.
28. Chamorro A, Revilla M, Obach V, Vargas M, Planas AM. The -174G/C polymorphism of the interleukin 6 gene is a hallmark of lacunar stroke and not other ischemic stroke phenotypes. Cerebrovasc Dis. 2005;19: 91-95.
29. Tso AR, Merino JG, Warach S. Interleukin-6 174G/C polymorphism and ischemic stroke: a systematic review. Stroke. 2007;38:3070-3075.
30. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens. 1996;14(suppl 2):s41-s46.
31. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
32. Woodward M. Epidemiology: Study Design and Data Analysis. 2nd ed. Boca Raton, Fla: Chapman and Hall/CRC Press; 2005.
33. Woodward M, Barzi F, Feigin V, Gu D, Huxley R, Nakamura K, Patel A, Ho S, Jamrozik K. Associations between high density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region. Eur Heart J. 2007;28:2653-2660.
34. Stuyt RJ, Netea MG, Verschueren I, Dinarello CA, Kullberg BJ, van der Meer JW. Interleukin-18 does not modulate the acute-phase response. J Endotoxin Res. 2005;11:85-88.
35. Marquardt L, Ruf A, Mansmann U, Winter R, Buggle F, Kallenberg K, Grau AJ. Inflammatory response after acute ischemic stroke. J Neurol Sci. 2005;236:65-71.
36. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005;17: 286-292.
37. Koenig W, Khuseyinova N, Baumert J, Thorand B, Loewel H, Chambless L, Meisinger C, Schneider A, Martin S, Kolb H, Herder C. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol. 2006;26:2745-2751.
38. Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003;34:623-631.
39. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-γ. Circ Res. 2002;90:e34-e38.